Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Gansner · SciRah

Researcher profile · Semantic Scholar

J. Gansner

Share profile

J. Gansner — researcher profile on SciRah

h-index: 8
Works: 34
Citations: 655

Most-cited papers

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
S. Garrelfs, Y. Frishberg, S. Hulton, M. Koren +21 more
2021New England Journal of Medicine403 citations Open access
Semantic Scholar
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
M. Michael, J. Groothoff, H. Shasha-Lavsky, J. Lieske +15 more
2022American Journal of Kidney Diseases81 citations Open access
Semantic Scholar
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial
W. Hayes, David J. Sas, D. Magen, H. Shasha-Lavsky +8 more
2022Pediatric nephrology (Berlin, West)39 citations Open access
Semantic Scholar
Understanding the regulation of vertebrate hematopoiesis and blood disorders: big lessons from a small fish
Anne L. Robertson, S. Avagyan, J. Gansner, L. Zon
2016FEBS Letters37 citations Open access
Semantic Scholar
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
S. Hulton, J. Groothoff, Y. Frishberg, M. Koren +18 more
2021Kidney International Reports28 citations Open access
Semantic Scholar
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
S. Garrelfs, Y. Frishberg, S. Hulton, M. Koren +19 more
2020Nephrology, Dialysis and Transplantation17 citations
Semantic Scholar
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial
J. Saland, John C. Lieske, J. Groothoff, Y. Frishberg +11 more
2024Kidney International Reports11 citations Open access
Semantic Scholar
Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial.
A. Sellier-Leclerc, D. Magen, H. Shasha-Lavsky, E. Simkova +15 more
2025American Journal of Kidney Diseases9 citations Open access
Semantic Scholar
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial
Y. Frishberg, Wesley N. Hayes, H. Shasha-Lavsky, David J. Sas +6 more
2024Frontiers in Pediatrics8 citations Open access
Semantic Scholar
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
S. Garrelfs, J. Gansner, J. Lieske
2021New England Journal of Medicine8 citations
Semantic Scholar
12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1
J. Saland, J. Groothoff, Y. Frishberg, S. Hulton +19 more
2020Journal of the American Society of Nephrology4 citations
Semantic Scholar
Hepatic plasminogen lowering with a galnac-conjugated siRNA reduces plasmin generation and fibrinolysis but has no effect on thrombin generation in rats and mice
Caitlin Cevasco, L. Ivanciu, J. Gansner, Rodney Camire +1 more
2025Blood3 citations
Semantic Scholar
POS-438 Long-term Treatment With Lumasiran: Results From the Phase 2 Open-Label Extension Study
D. Magen, J. Groothoff, S. Hulton, J. Harambat +7 more
2022Kidney International Reports3 citations Open access
Semantic Scholar
PD05-03 EFFICACY AND SAFETY OF LUMASIRAN IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1: 24-MONTH ANALYSIS OF THE ILLUMINATE-A TRIAL
J. Lieske, J. Groothoff, Y. Frishberg, A. Sellier-Leclerc +10 more
2022Journal of Urology2 citations
Semantic Scholar
Long-term Lumasiran Therapy Final Results from a Phase 2 Open-label Extension Study in Primary Hyperoxaluria.
Y. Frishberg, J. Groothoff, S. Hulton, J. Harambat +7 more
2025Nephrology, Dialysis and Transplantation1 citations Open access
Semantic Scholar
MP10-01 EFFICACY AND SAFETY OF LUMASIRAN IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1: 36-MONTH ANALYSIS OF THE ILLUMINATE-A TRIAL
J. Lieske, J. Saland, J. Groothoff, Y. Frishberg +11 more
2023Journal of Urology1 citations
Semantic Scholar
Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study
J. Lieske, J. Groothoff, Y. Frishberg, S. Garrelfs +12 more
2023Kidney Medicine1 citations
Semantic Scholar
Phase 1 study of the RNA interference therapeutic ALN-HSD in healthy adults and patients with non-alcoholic steatohepatitis
A. Sanyal, J. Täubel, P. Badri, Sarah Bond +7 more
2023Journal of Hepatology1 citations
Semantic Scholar
Lumasiran for Patients With Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial
Y. Frishberg, M. Michael, J. Groothoff, H. Shasha-Lavsky +12 more
2022Journal of the American Society of Nephrology1 citations
Semantic Scholar
OC 12.3 Low plasminogen levels are not associated with an increased risk of arterial thrombosis
L. Krohn, Martina Lundberg Slingsby, A. Murad, Luke Ward +3 more
2026Research and Practice in Thrombosis and Haemostasis0 citations Open access
Semantic Scholar
Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1
Y. Frishberg, J. Saland, J. Lieske, W. Du +7 more
2025American Society of Nephrology. Clinical Journal0 citations Open access
Semantic Scholar
#2388 Long-term efficacy and safety in the 60-month, Phase 3 ILLUMINATE-B trial of lumasiran in infants and young children with primary hyperoxaluria type 1
Y. Frishberg, Wesley N. Hayes, Efrat Ben-Shalom, H. Shasha-Lavsky +8 more
2025Nephrology, Dialysis and Transplantation0 citations
Semantic Scholar
#190 Long-term treatment with lumasiran: final results from the phase 2 open-label extension study
Y. Frishberg, J. Groothoff, S. Hulton, J. Harambat +7 more
2024Nephrology, Dialysis and Transplantation0 citations Open access
Semantic Scholar
#4551 DEVELOPMENT OF AN X-RAY–BASED BONE OXALOSIS GRADING SCALE TO ASSESS OXALATE ACCUMULATION IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1
Jonathan C. Baker, J. Bacchetta, L. Cowen, J. Gansner +3 more
2023Nephrology, Dialysis and Transplantation0 citations Open access
Semantic Scholar
NS-AUA 2023 ABSTRACTS
Stephen Leslie, M. Michael, D. Magen, Wesley N. Hayes +30 more
20230 citations
Semantic Scholar
Unlocking the Potential of Genetic Testing: Insights into Primary Hyperoxaluria and Monogenic Kidney Stone Disease
John C. Lieske, D. Magen, A. Sellier-Leclerc, H. Shasha-Lavsky +14 more
2023Journal of the American Society of Nephrology0 citations
Semantic Scholar
FC069: Pharmacokinetics and Pharmacodynamics of Lumasiran: Analysis of Four Clinical Studies
J. Gansner, G. Robbie, B. Habtemariam
2022Nephrology, Dialysis and Transplantation0 citations
Semantic Scholar
FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial
J. Groothoff, M. Michael, H. Shasha-Lavsky, J. Lieske +14 more
2022Nephrology, Dialysis and Transplantation0 citations
Semantic Scholar
MO047STABLE EGFR IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 TREATED WITH LUMASIRAN, REGARDLESS OF KIDNEY FUNCTION AT START OF TREATMENT
W. Hayes, S. Garrelfs, David J. Sas, J. Lieske +4 more
2021Nephrology, Dialysis and Transplantation0 citations
Semantic Scholar
MP07-09 12-MONTH ANALYSIS OF ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN: SUSTAINED OXALATE LOWERING AND KIDNEY STONE EVENT RATES IN PRIMARY HYPEROXALURIA TYPE 1
D. Assimos, J. Saland, J. Groothoff, Y. Frishberg +20 more
20210 citations Open access
Semantic Scholar
Modeling the Risk of Progression to Kidney Failure in Patients with Primary Hyperoxaluria Type 1 Treated with Lumasiran Relative to a Natural History Cohort Not Treated with Lumasiran
J. Lieske, Kristin C. Mara, D. Danese, J. Gansner +2 more
2021Journal of the American Society of Nephrology0 citations
Semantic Scholar
FC 013LUMASIRAN DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1
H. Shasha-Lavsky, S. Garrelfs, David J. Sas, J. Lieske +5 more
20210 citations Open access
Semantic Scholar
MP07-08 EFFECT OF LUMASIRAN ON KIDNEY STONES AND NEPHROCALCINOSIS IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1
J. Lieske, S. Garrelfs, M. Michael, J. Saland +5 more
20210 citations
Semantic Scholar
Mechanisms of Copper-Dependent Notochord Formation in Zebrafish
J. Gansner
20100 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Y. Frishberg×25
Invite
Y. Frishberg — researcher profile on SciRah
D. Magen×21
Invite
D. Magen — researcher profile on SciRah
H. Shasha-Lavsky×19
Invite
H. Shasha-Lavsky — researcher profile on SciRah
A. Sellier-Leclerc×19
Invite
A. Sellier-Leclerc — researcher profile on SciRah

×16

Invite

J. Lieske — researcher profile on SciRah

Invite

S. Hulton — researcher profile on SciRah

J. Groothoff×11

Invite

J. Groothoff — researcher profile on SciRah

S. Garrelfs×10

Invite

S. Garrelfs — researcher profile on SciRah

Invite

M. Michael — researcher profile on SciRah

David J. Sas×9

Invite

David J. Sas — researcher profile on SciRah

Tracy L. Mcgregor×9

Invite

Tracy L. Mcgregor — researcher profile on SciRah

Invite

T. Ngo — researcher profile on SciRah